Today, Axon Neuroscience has announced the results of the Phase II trial for AADvac1, its first-in-class vaccine aimed at slowing down the progression of Alzheimer’s Disease The Phase II ADAMANT trial ...

LONDON, GB / ACCESS Newswire / April 28, 2025 / The Progressive Supranuclear Palsy (PSP) Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan ...

LONDON - The Progressive (NYSE:PGR) Supranuclear Palsy (PSP) Trial Platform, a collaborative clinical trial initiative, has recently announced the inclusion of two drug candidates, AADvac1 by Axon ...

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens LONDON, GB / ACCESS Newswire / April 28, 2025 / The Progressive ...

Biology textbooks may need a revision, say Johns Hopkins Medicine scientists, who present new evidence that an armlike structure of mammalian brain cells may be a different shape than scientists have ...

Memories and learning processes are based on changes in the brain’s neuronal connections and, as a result, in signal transmission between neurons. For the first time, DZNE researchers have observed an ...